Aldurazyme (laronidase) - prescribing information
U.S. prescribing information for laronidase, dosed 0.58 mg/kg IV once weekly for MPS I.
U.S. Food and Drug Administration
The sources behind every topic — consensus guidelines, reviews and prescribing information, with the year and organisation that published them. Open a title to read it at the source.
U.S. prescribing information for laronidase, dosed 0.58 mg/kg IV once weekly for MPS I.
U.S. Food and Drug Administration
U.S. prescribing information for galsulfase, dosed 1 mg/kg IV once weekly for MPS VI.
U.S. Food and Drug Administration
U.S. prescribing information for Fayuvi gene therapy, FDA-approved for neurologic manifestations of MPS IIIA with preserved neurodevelopmental function.
U.S. Food and Drug Administration
GeneReviews chapter on Pompe disease, covering CRIM status, immune tolerance induction and the targeted treatment of infantile-onset disease.
GeneReviews, University of Washington
U.S. prescribing information for vestronidase alfa, dosed 4 mg/kg IV every 2 weeks for MPS VII.
U.S. Food and Drug Administration
A pediatric clinical guide to the mucopolysaccharidoses: recognition of the clinical pattern, biochemical and molecular testing, subtype-specific therapy, and surveillance and perioperative planning.
Pediatric metabolics / MPS clinical guide
2026
U.S. prescribing information for tividenofusp alfa-eknm, an accelerated-approval enzyme replacement for the neurologic manifestations of MPS II.
U.S. Food and Drug Administration
2026
Evidence-based recommendations for phenylalanine hydroxylase deficiency, including lifelong treatment when untreated phenylalanine exceeds 360 micromol/L and a treatment target of 360 micromol/L or le
American College of Medical Genetics and Genomics
2025
The Sanfilippo syndromes (MPS IIIA-D): progressive neurocognitive decline with mild somatic features, diagnosis and supportive management.
GeneReviews, University of Washington
2024
Peer-reviewed chapter on Noonan syndrome covering diagnosis, cardiac surveillance, management and genetic counselling.
University of Washington, NCBI Bookshelf
2024
Morquio A syndrome: skeletal disease, the role of urinary GAGs and enzyme testing, elosulfase alfa therapy and cervical spine surveillance.
GeneReviews, University of Washington
2024
The X-linked Hunter syndrome: clinical features, enzyme and molecular testing, idursulfase therapy and the approach to neuronopathic disease.
GeneReviews, University of Washington
2024
Diagnosis, management and genetic counselling for MPS I, including the severe Hurler spectrum and the role of early haematopoietic stem cell transplantation.
GeneReviews, University of Washington
2024
The working standard for testing criteria, surveillance schedules and risk-reducing surgery thresholds in hereditary breast, ovarian and pancreatic cancer.
National Comprehensive Cancer Network
2024
Diagnosis and treatment of biotinidase deficiency, including free biotin dosing for profound and partial deficiency and the need for hearing and vision assessment.
GeneReviews, University of Washington
2024
Management of MCAD deficiency, including the acute illness glucose infusion of 1.5 times maintenance or a GIR of 10-12 mg/kg/min and fasting prevention.
GeneReviews, University of Washington
2024
Peer-reviewed, regularly updated chapters per condition covering diagnosis, management and genetic counselling. The first place to check after the differential.
University of Washington, NCBI Bookshelf
2024
Clinical description, diagnosis and management of MSUD, including the inpatient branched-chain amino acid and BCAA-free formula regimen.
GeneReviews, University of Washington
2024
Assessment and management of hypoglycaemia in children, including the critical sample during hypoglycaemia and initial dextrose therapy.
Royal Children's Hospital Melbourne
2024
Emergency and ward approach to suspected inborn errors of metabolism, including initial assessment, critical samples and the first pattern-based differential.
Royal Children's Hospital Melbourne
2024
Diagnosis and management of tyrosinemia type I, including nitisinone dosing, dietary restriction and the monitoring schedule.
GeneReviews, University of Washington
2024
A neonatal pathway for hyperammonaemia giving example levocarnitine and hydroxocobalamin regimens used in suspected organic acidaemia.
Nationwide Children's Hospital
2024
Clinic and family resources on diagnosis, aortic surveillance, medication, pregnancy and the transition to adult care in Marfan syndrome.
The Marfan Foundation
2024
Clinician and family resources covering fracture management, bisphosphonate therapy, growth, hearing, pain and transition to adult services.
Osteogenesis Imperfecta Foundation
2024
Recognition and treatment of hypoketotic hypoglycaemia during fasting or febrile illness, the glucose infusion rates used to reverse catabolism, avoidance of lipid loads in the acute phase and the saf
British Inherited Metabolic Disease Group (BIMDG)
2023
The classification of genetic skeletal disorders, used to place a dysplasia in the right group and to guide the diagnostic pathway.
American Journal of Medical Genetics
2023
The BIMDG emergency framework for a child who presents unwell with a suspected metabolic disorder: stop protein and feeds, start the emergency regimen, take the critical samples before treatment and d
British Inherited Metabolic Disease Group (BIMDG)
2023
Diagnostic strategy for suspected urea cycle defects, protein prescription and essential amino acid supplementation, citrulline and arginine dosing, sickle-cell-style monitoring, and the sick-day plan
British Inherited Metabolic Disease Group (BIMDG)
2023
The emergency regimen used across inherited metabolic disorders: when to start glucose polymer drinks, volumes and intervals by age, how to record progress, and the red flags that mean the child needs
British Inherited Metabolic Disease Group (BIMDG)
2023
Emergency regimen for urea cycle disorders during illness or fasting: glucose polymer drinks, stopping dietary protein and when to admit for intravenous ammonia scavengers.
British Inherited Metabolic Disease Group (BIMDG)
2023
Sick-day protocol for maple syrup urine disease: withholding leucine, high-calorie glucose drinks and urgent admission for leucine removal if encephalopathy develops.
British Inherited Metabolic Disease Group (BIMDG)
2023
Diagnosis and lifelong dietary management of galactosaemia, including the lactose-free diet and monitoring for long-term complications.
British Inherited Metabolic Disease Group (BIMDG)
2023
Dietary and vitamin treatment of homocystinuria, target total homocysteine levels and monitoring for thrombotic and ocular complications.
British Inherited Metabolic Disease Group (BIMDG)
2023
Disease overview of thanatophoric dysplasia: definition, epidemiology, prenatal ultrasound findings, inheritance and the differential diagnosis of the lethal dysplasias.
Orphanet
2023
Label dosing for carglumic acid in acute hyperammonaemia due to NAGS deficiency and in organic acidaemias, with renal adjustment guidance.
European Medicines Agency
2023
Health supervision across childhood and adolescence in Down syndrome, from cardiac screening to hearing, thyroid and growth checks.
American Academy of Pediatrics
2022
International multidisciplinary consensus on diagnosis, growth, foramen magnum and spinal stenosis, hearing, sleep and lifelong care in achondroplasia.
International Achondroplasia Consensus Group
2022
British Inherited Metabolic Disease Group guideline on argininosuccinic aciduria (argininosuccinate lyase deficiency): confirming the diagnosis biochemically, dietary protein restriction, arginine sup
British Inherited Metabolic Disease Group (BIMDG)
2022
Dietary treatment of phenylketonuria, target phenylalanine ranges by age, and the monitoring schedule for children and adults on a low-phenylalanine diet.
British Inherited Metabolic Disease Group (BIMDG)
2022
Emergency management of glycogen storage disorders during intercurrent illness, including frequent glucose polymer, cornstarch dosing and admission thresholds for hypoglycaemia.
British Inherited Metabolic Disease Group (BIMDG)
2022
Consensus recommendations on the diagnosis and therapeutic management of hyperammonaemia in paediatric and adult patients, covering the emergency approach, nitrogen scavengers and monitoring.
Nutrients (MDPI)
2022
Home and hospital sick-day management for medium-chain acyl-CoA dehydrogenase deficiency: glucose polymer drinks at set intervals, when to escalate to intravenous glucose, and the follow-up patients a
British Inherited Metabolic Disease Group (BIMDG)
2022
Emergency treatment of propionic, methylmalonic and isovaleric acidaemia during decompensation, carnitine and vitamin B12 use, and the surveillance that matters long term: growth, cardiac function, re
British Inherited Metabolic Disease Group (BIMDG)
2022
Stepwise control of plasma ammonia: stop protein intake, give intravenous glucose to suppress catabolism, add nitrogen scavengers, and move to extracorporeal removal when ammonia stays above the agree
British Inherited Metabolic Disease Group (BIMDG)
2022
Consensus management guidelines for methylmalonic and propionic acidaemia, covering acute decompensation, carnitine and cobalamin therapy and long-term diet.
Journal of Inherited Metabolic Disease
2021
European principles of management: surveillance schedule, thresholds for foramen magnum and spinal complications, and coordinated multidisciplinary follow-up.
European Achondroplasia Forum
2021
The reference for phenotype-first dysmorphology: pattern recognition, differential lists and the questions to ask before ordering a test.
Elsevier
2021
Diagnosis and emergency management of fatty acid oxidation defects, with emergency regimens and follow-up for MCAD and VLCAD deficiency.
Journal of Inherited Metabolic Disease
2020
A paediatric kidney replacement consensus defining when to start continuous kidney replacement therapy for hyperammonaemia, including the ammonia thresholds for rapid neurologic deterioration, severe
Nature Reviews Nephrology
2020
U.S. label starting doses of sapropterin by age and the 5-20 mg/kg/day titration range for BH4-responsive PAH deficiency.
U.S. Food and Drug Administration
2020